OncoMatch/Clinical Trials/NCT06690840
Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
Is NCT06690840 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Atezolizumab in combination with Cyclophosphamide and Vinorelbine for triple negative breast cancer.
Treatment: Atezolizumab in combination with Cyclophosphamide and Vinorelbine — Triple-negative breast cancer (TNBC) is among the most aggressive and lethal types of breast cancer, and currently available therapies have an unsatisfactory impact on patients' survival. The primary aim of this clinical trial is to evaluate efficacy in terms of Overall Response Rate (ORR) of atezolizumab plus cyclophosphamide and vinorelbine in first line patients with unresectable locally advanced or metastatic TNBC patients, previously treated with anti-programmed cell death ligand-1 (PD-L1) or anti-programmed cell death-1 (PD-1) - containing regimens, in the neoadjuvant/adjuvant setting.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) overexpression (immune cell >1% using ventana sp142 assay)
Required: HER2 (ERBB2) wild-type
Required: ESR1 wild-type
Required: PR (PGR) wild-type
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1/PD-L1 therapy — neoadjuvant/adjuvant
who have received an anti-PD-1/PD-L1 containing regimen in the neoadjuvant/adjuvant setting
Cannot have received: chemotherapy or targeted systemic therapy (including endocrine therapy) or immunotherapy
Exception: neoadjuvant/adjuvant anti-PD-1/PD-L1 allowed
No prior chemotherapy or targeted systemic therapy (including endocrine therapy) or immunotherapy for inoperable locally advanced or metastatic TNBC
Lab requirements
Kidney function
adequate organ (kidney, liver) function
Liver function
adequate organ (kidney, liver) function
Demonstrate adequate organ (kidney, liver) function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06690840 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 overexpression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify